Improved Survival in Patients with Multiple Myeloma Treated with DMVM plus IFN-α

Teruo Kitani; Yukihiro Tokumine; Tohru Masaoka; Atsushi Horiuchi; Eizo Kakishita; Takashi Kageyama; Noriyuki Tatsumi; Jun Kuyama; Kunio Hayashi; Machiko Tsukaguchi; Hiroya Kawagoe; Hedeki Fujitake; Tadahiro Tsubakio; Kaori Nasu; Yoshiteru Konaka; Tsuyoshi Yonezawa; Kiyoyasu Nagai

doi:10.3960/jslrt.45.71

Original Articles

Improved Survival in Patients with Multiple Myeloma Treated with DMVM plus IFN-α

Teruo Kitani, Yukihiro Tokumine, Tohru Masaoka, Atsushi Horiuchi, Eizo Kakishita, Takashi Kageyama, Noriyuki Tatsumi, Jun Kuyama, Kunio Hayashi, Machiko Tsukaguchi, Hiroya Kawagoe, Hedeki Fujitake, Tadahiro Tsubakio, Kaori Nasu, Yoshiteru Konaka, Tsuyoshi Yonezawa, Kiyoyasu Nagai

Author information

Keywords: DMVM+IFN-α, multiple myeloma

JOURNAL FREE ACCESS

2005 Volume 45 Issue 2 Pages 71-79

DOI https://doi.org/10.3960/jslrt.45.71

Details

Abstract

We examined effects of combination chemotherapy with dexamethasone, melphalan, vincristine, and MCNU (DMVM), plus IFN-α in patients with previously untreated and treated multiple myeloma (MM). In the study, 78 previously untreated and 47 treated MM patients were evaluated. The overall response rate was 76% [27% complete response (CR)] : 85% [37% CR] in previously untreated patients and 62% [11% CR] in previously treated patients. The 50% survival time was 45.3 months for untreated patients and 30.1 months for previously treated patients. This regimen is effective in producing a high CR rate and prolonging survival duration of MM patients.

Corresponding author

Register with J-STAGE for free!